Skip to main content

Market Overview

Johnson & Johnson Posts Upbeat Q3 Earnings, But Sales Drop


Johnson & Johnson (NYSE: JNJ) reported better-than-expected earnings for the third quarter and lifted its earnings forecast for the full year. However, the company reported a decline in its quarterly sales.

The New Brunswick, New Jersey-based company reported quarterly net earnings of $3.36 billion, or $1.20 per share, compared to $4.75 billion, or $1.66 per share, in the year-earlier quarter. Excluding items, the company's adjusted earnings came in at $1.49 per share.

Its sales dropped 7.4 percent year-over-year to $17.1 billion for the third quarter. However, analysts were expecting earnings of $1.45 per share on revenue of $17.5 billion.

The average estimate among 111 Estimize users was for earnings of $1.46 per share and revenue of $17.46 billion.

Domestic sales slipped 0.6 percent, while international sales dipped 13.7 percent.

Worldwide consumer sales dropped 7.7 percent to $3.3 billion for the third quarter, while worldwide pharmaceutical sales slipped 7.4 percent to $7.7 billion for the quarter. Worldwide medical devices sales declined 7.3 percent to $6.1 billion.

The company's board also announced a $10 billion share buyback program.

"New and core products drove solid underlying growth for Johnson & Johnson in the quarter," said Alex Gorsky, Chairman and Chief Executive Officer. "Consistent with the plans we've laid out for the year, we're focusing our portfolio and are advancing our innovation agenda to expand our leadership position in key categories while seeking new opportunities for growth. Our dedicated employees are committed to improving healthcare and making a difference in the lives of patients and consumers worldwide."

J&J lifted its adjusted earnings forecast for the full year to $6.15 to $6.20 per share.

J&J shares rose 0.95 percent to $96.90 in pre-market trading.


Related Articles (JNJ)

View Comments and Join the Discussion!

Posted-In: profitEarnings News Guidance

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at